Drug
Fasinumab clinical trials
Also written REGN475 and MT-5547.
- studies test it
- 17
- open now
- 0
- in phase 3
- 7
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2009 | 5 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Regeneron Pharmaceuticals (16) · Tanabe Pharma Corporation (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fasinumab is read from its arms, and is right about nine times in ten.
Testing it · 17
- Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe PainCompletedPhase 2/3Tanabe Pharma CorporationNCT03245008Written as MT-5547
- Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and HipTerminatedPhase 2Regeneron PharmaceuticalsNCT03949673Written as Fasinumab
- Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or HipCompletedPhase 3Regeneron PharmaceuticalsNCT02683239Written as Fasinumab
- Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or KneeCompletedPhase 2Regeneron PharmaceuticalsNCT03691974Written as Fasinumab
- Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipCompletedPhase 3Regeneron PharmaceuticalsNCT03304379Written as Fasinumab
- A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipCompletedPhase 3Regeneron PharmaceuticalsNCT03161093Written as Fasinumab
- Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or KneeTerminatedPhase 3Regeneron PharmaceuticalsNCT03285646Written as Fasinumab
- To Assess the Patients' Ability to Self-Administer FasinumabCompletedPhase 1Regeneron PharmaceuticalsNCT03491904Written as Fasinumab AI
- A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back PainCompletedPhase 2/3Regeneron PharmaceuticalsNCT02620020Written as Fasinumab
- Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or HipCompletedPhase 2/3Regeneron PharmaceuticalsNCT02447276Written as REGN475
- Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Regeneron PharmaceuticalsNCT02516618Written as Fasinumab
- A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the KneeWithdrawnPhase 2Regeneron PharmaceuticalsNCT01239017Written as REGN475
- Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis PainTerminatedPhase 2Regeneron PharmaceuticalsNCT01001923Written as REGN475/SAR164877
- Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture PainTerminatedPhase 2Regeneron PharmaceuticalsNCT01001715Written as REGN475/SAR164877
- A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy SubjectsCompletedPhase 1Regeneron PharmaceuticalsNCT00856310Written as REGN475 (SAR164877)
- A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the KneeCompletedPhase 1/2Regeneron PharmaceuticalsNCT00944892Written as REGN475
- A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic PainCompletedPhase 2Regeneron PharmaceuticalsNCT00991172Written as REGN475
Codes
What other systems call fasinumab · ClinicalTrials.gg INT000929
- MeSH (NLM) C000626997fasinumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 11T51Q3082FASINUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5436808FasinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166446FasinumabOne source FDA
- DrugBank DB12157One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626997 | fasinumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 11T51Q3082 | FASINUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5436808 | Fasinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166446 | Fasinumab | One source FDA |
| DrugBank | DB12157 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.